LENZ LENZ THERAPEUTICS INC

LENZ Therapeutics to Host Commercial Day on April 15, 2025

LENZ Therapeutics to Host Commercial Day on April 15, 2025

Event to highlight the commercialization strategy and progress towards the potential approval of LNZ100 for the treatment of presbyopia

SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that it will host a Commercial Day to highlight the commercialization strategy and progress towards the potential approval of LNZ100 for the treatment of presbyopia. The event will take place on Tuesday, April 15, 2025, from 2:00 p.m. – 4:00 p.m. EST.

The event will include presentations by management to feature key updates as the Company approaches the potential approval and launch of LNZ100, including commercialization strategies, supply chain and product distribution readiness, perspectives from Key Opinion Leader and Eye Care Professionals and additional special guest speakers.

A live audio webcast of the presentation will be available through the link and on the Events section of the Investor Relations page of the LENZ Therapeutics website at . A replay of the webcast will be available on the Company’s website for 12 months following the event.

About LENZ Therapeutics

LENZ Therapeutics is a pre-commercial biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in patients with presbyopia. LENZ’s product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase 3 CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. The U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025 for LNZ100. LENZ is committed to commercializing an ideal pharmaceutical presbyopia solution that enhances vision for “all eyes, all day”. LENZ is headquartered in San Diego, California. For more information, visit: .

Contacts:

Dan Chevallard

LENZ Therapeutics



EN
03/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on LENZ THERAPEUTICS INC

 PRESS RELEASE

LENZ Therapeutics to Report First Quarter 2025 Financial Results and R...

LENZ Therapeutics to Report First Quarter 2025 Financial Results and Recent Corporate Highlights on May 7th, 2025 SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced it will host a webcast on Wednesday, May 7th, 2025, at 4:30 p.m. EDT to report its first quarter 2025 financial results and recent corporate highlights. To...

 PRESS RELEASE

LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial ...

LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 Upon FDA approval, commercial launch activities to commence immediately with LNZ100 product availability anticipated in the fourth quarter of 2025 Cash, cash equivalents and marketable securities of $209.1 million as of December 31, 2024; cash runway anticipated to extend to post-launch positive operating cash flow Company to host a conference call today at 4...

 PRESS RELEASE

LENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financia...

LENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March 19, 2025 SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced it will host a webcast on Wednesday, March 19, 2025, at 4:30 p.m. EST to report its fourth quarter and full year 2024 financial results and ...

 PRESS RELEASE

LENZ Therapeutics to Host Commercial Day on April 15, 2025

LENZ Therapeutics to Host Commercial Day on April 15, 2025 Event to highlight the commercialization strategy and progress towards the potential approval of LNZ100 for the treatment of presbyopia SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that it will host a Commercial Day to highlight the commercialization str...

 PRESS RELEASE

LENZ Therapeutics to Participate in Upcoming Investor Conferences

LENZ Therapeutics to Participate in Upcoming Investor Conferences SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that company management will participate in the following upcoming investor conferences: TD Cowen 45th Annual Health Care Conference (Boston, MA)Management is scheduled to provide a corporate presentation...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch